Biogen’s potential blockbuster MS drug BG-12 has met its primary endpoint in a late-stage trial. BG-12 (dimethyl fumarate) tablets …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

